Ennov

Who owns Ennov?

Ennov is currently owned by Ardian through Ardian Buyout Fund VII (2017 vintage), since 2026.

Hand-verified · updated 2026-05-27

About Ennov

Ennov is a Paris-based software company whose cloud platform helps life sciences organizations manage the content, data and regulated processes that govern drug and medical-device development. Its unified suite spans Regulatory Affairs, Pharmacovigilance, Quality, Clinical and Commercial functions, combining document management, workflow, structured data and analytics with AI capabilities so that companies can meet the requirements of authorities such as the FDA and EMA within a single system rather than a patchwork of legacy point solutions. It competes in the vertical, compliance-driven SaaS segment for pharmaceuticals, biotech, medical devices and clinical research, where audit-readiness and switching costs favor incumbents. According to the company, its software serves roughly 450 to 650 life sciences customers and more than 500,000 users across around 30 countries, supported by offices in the United States, the United Kingdom, continental Europe and Asia. Ennov reports a 100 percent client audit success rate and recognition from Gartner as a global provider across electronic document management, regulatory information management, pharmacovigilance and eTMF.

Ownership journey

Ennov was founded in Paris in 1999 by Olivier Paris and Laure Bros, and Olivier Paris remains founder and chief executive more than 25 years later. The business grew as a founder-led specialist in software for regulated content and data in life sciences, expanding internationally without publicly disclosed private-equity ownership for most of its history. In 2026 Ardian entered the company through a strategic growth investment announced in May and expected to close in the second quarter, taking a stake alongside management. Ardian is named as an active shareholder from 2026; no exit or secondary transaction involving its stake has been recorded.

Under PE ownership

The 2026 growth investment was framed around accelerating Ennov's next phase rather than restructuring an established, profitable software business. The stated priorities for the new capital are AI innovation across the platform, faster global go-to-market execution and continued investment in the product offering, building on the AI layer Ennov has added to its document, workflow and data modules. Because the transaction was only announced in May 2026 and set to complete late in the second quarter, measurable operating change under the investment remains early. Ennov enters the partnership already at scale, citing more than 500,000 users, a customer base in the hundreds and operating metrics including a 96 percent annual maintenance renewal rate and 98.5 percent on-time project delivery, which the investment is intended to extend into new markets and AI-enabled use cases.